Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion

Abstract

The present invention relates to a pharmaceutical composition including loratadine or a pharmaceutically acceptable form thereof, and phenylephrine or a pharmaceutically acceptable form thereof, for treating upper respiratory / mucosal congestion, optionally by administering to a patient four times a day.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. Ser. No. 11 / 922,271 filed on 20 Dec. 2007 which is a national phase application from PCT / NZ2005 / 000132, with an international filing date and earliest priority date of 17 Jun. 2005.INTRODUCTION[0002]The present invention relates to a pharmaceutical composition including loratadine, its use in the treatment of upper respiratory mucosal congestion and a method of administration of the composition. Particularly, though not exclusively, the invention relates to a pharmaceutical composition including loratadine in an amount suitable for administration a maximum of 4 times a day, and a second active that is phenylephrine, or a salt thereof.BACKGROUND[0003]Upper respiratory mucosal congestion caused by infections such as the common cold and influenza, or allergic rhinitis, can lead to a number of nasal and ocular symptoms. These include rhinitis and sinusitis, nasal and sinus congestion or excessive secre...

AI Technical Summary

Benefits of technology

The patent describes a pharmaceutical composition that includes loratadine and phenylephrine for the treatment of upper respiratory / mucosal congestion. The composition can be administered four times a day and is typically in a solid dosage form, such as a pill, capsule, or tablet. The use of the pharmaceutical composition is described as a treatment option for patients with upper respiratory / mucosal congestion.

Problems solved by technology

However, in comparison to loratadine, cetirizine has been reported to have a higher incidence of adverse drug reactions (ADRs), especially central nervous system ADRs.

However, there are adverse effects that can occur at peak concentration and also with end-of-dose diminution of effect.

However, products containing pseudoephedrine are now subject to abuse problems associated with illicit drug use in the community.

This has resulted in pharmacy hold-ups, stolen stock from warehouses and significant related crime.

The resulting crime, and its effects on the outlets which supply these medications to the market, means that some outlets are choosing not to stock these products, or at least restrict their availability.

This makes them less accessible to those with a genuine need for the medications.